|Bid||0.4150 x 3200|
|Ask||0.4200 x 3000|
|Day's Range||0.4070 - 0.4450|
|52 Week Range||0.1000 - 4.8300|
|Beta (5Y Monthly)||2.49|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
Benzinga Pro's Stocks To Watch For Friday Tesla (TSLA) - Morgan Stanley analyst Adam Jonas raised his bull-case price target on the stock from $440 to $500. The analyst maintains an Equal-Weight rating ...
The week was a busy one for Onconova Therapeutics Inc., which signed a licensing deal for its lead product candidate and embarked on a multimillion-dollar public stock offering. The Bucks County biopharmaceutical company is focused on developing products to treat cancer. It’s lead new drug candidate, rigosertib, is in late-stage clinical testing as both an oral and intravenous therapy for patients at high risk for developing myelodysplastic syndromes or MDS.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...
Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.